Literature DB >> 3771793

Familial apolipoprotein E deficiency.

E J Schaefer, R E Gregg, G Ghiselli, T M Forte, J M Ordovas, L A Zech, H B Brewer.   

Abstract

A unique kindred with premature cardiovascular disease, tubo-eruptive xanthomas, and type III hyperlipoproteinemia (HLP) associated with familial apolipoprotein (apo) E deficiency was examined. Homozygotes (n = 4) had marked increases in cholesterol-rich very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL), which could be effectively lowered with diet and medication (niacin, clofibrate). Homozygotes had only trace amounts of plasma apoE, and accumulations of apoB-48 and apoA-IV in VLDL, IDL, and low density lipoproteins. Radioiodinated VLDL apoB and apoE kinetic studies revealed that the homozygous proband had markedly retarded fractional catabolism of VLDL apoB-100, apoB-48 and plasma apoE, as well as an extremely low apoE synthesis rate as compared to normals. Obligate heterozygotes (n = 10) generally had normal plasma lipids and mean plasma apoE concentrations that were 42% of normal. The data indicate that homozygous familial apoE deficiency is a cause of type III HLP, is associated with markedly decreased apoE production, and that apoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3771793      PMCID: PMC423806          DOI: 10.1172/JCI112704

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins.

Authors:  G Utermann; M Jaeschke; J Menzel
Journal:  FEBS Lett       Date:  1975-08-15       Impact factor: 4.124

2.  Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogen.

Authors:  R S Kushwaha; W R Hazzard; C Gagne; A Chait; J J Albers
Journal:  Ann Intern Med       Date:  1977-11       Impact factor: 25.391

3.  High density lipoprotein distribution. Resolution and determination of three major components in a normal population sample.

Authors:  D W Anderson; A V Nichols; S S Pan; F T Lindgren
Journal:  Atherosclerosis       Date:  1978-02       Impact factor: 5.162

4.  Human chylomicron apolipoprotein metabolism.

Authors:  E J Schaefer; L L Jenkins; H B Brewer
Journal:  Biochem Biophys Res Commun       Date:  1978-01-30       Impact factor: 3.575

Review 5.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-01-26       Impact factor: 91.245

6.  Abrnomal lipoprotein patterns in human serum as determined by agarose gel electrophoresis.

Authors:  N M Papadopoulos
Journal:  Clin Chem       Date:  1979-11       Impact factor: 8.327

7.  Radioimmunoassay studies of human apolipoprotein E.

Authors:  C B Blum; L Aron; R Sciacca
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

8.  Apolipoprotein A-I, A-II and C-II in black and white residents of Evans County.

Authors:  H A Tyroler; G Heiss; G Schonfeld; G Cooper; S Heyden; C G Hames
Journal:  Circulation       Date:  1980-08       Impact factor: 29.690

9.  Plasma-triglycerides in regulation of H.D.L.-cholesterol levels.

Authors:  E J Schaefer; R I Levy; D W Anderson; R N Danner; H B Brewer; W C Blackwelder
Journal:  Lancet       Date:  1978-08-19       Impact factor: 79.321

10.  Familial apolipoprotein A-I and C-III deficiency, variant II.

Authors:  E J Schaefer; J M Ordovas; S W Law; G Ghiselli; M L Kashyap; L S Srivastava; W H Heaton; J J Albers; W E Connor; F T Lindgren
Journal:  J Lipid Res       Date:  1985-09       Impact factor: 5.922

View more
  65 in total

1.  Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT.

Authors:  Kyriakos E Kypreos; Vassilis I Zannis
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

2.  Severe xanthomatosis associated with familial apolipoprotein E deficiency.

Authors:  G Feussner
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

3.  Domains of apoE4 required for the biogenesis of apoE-containing HDL.

Authors:  Alexander M Vezeridis; Angeliki Chroni; Vassilis I Zannis
Journal:  Ann Med       Date:  2011-06       Impact factor: 4.709

4.  Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat.

Authors:  Chunyu Zheng; Katsunori Ikewaki; Brian W Walsh; Frank M Sacks
Journal:  J Lipid Res       Date:  2006-05-09       Impact factor: 5.922

5.  Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.

Authors:  Margaret R Diffenderfer; Margaret E Brousseau; John S Millar; P Hugh R Barrett; Chorthip Nartsupha; Peter M Schaefer; Megan L Wolfe; Gregory G Dolnikowski; Daniel J Rader; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2012-04-02       Impact factor: 5.922

6.  ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma.

Authors:  Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Thomas Gautier; Patrick C N Rensen; Daniel J Rader; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2012-03-01       Impact factor: 5.922

7.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

8.  Allele-dependent thermodynamic and structural perturbations in ApoE variants associated with the correction of dyslipidemia and formation of spherical ApoE-containing HDL particles.

Authors:  Dimitra Georgiadou; Angeliki Chroni; Konstantinos Drosatos; Kyriakos E Kypreos; Vassilis I Zannis; Efstratios Stratikos
Journal:  Atherosclerosis       Date:  2012-11-23       Impact factor: 5.162

Review 9.  The fat-fed apolipoprotein E knockout mouse brachiocephalic artery in the study of atherosclerotic plaque rupture.

Authors:  Andrew R Bond; Christopher L Jackson
Journal:  J Biomed Biotechnol       Date:  2010-11-07

10.  Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.

Authors:  T Demant; D Bedford; C J Packard; J Shepherd
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.